Biofrontera Inc. (BFRI)
USD 0.69
(-4.57%)
USD 0.69
(-4.57%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 27.93 Million USD | -45.11% |
| 2022 | 50.88 Million USD | -4.39% |
| 2021 | 53.21 Million USD | 120.48% |
| 2020 | 24.13 Million USD | -16.05% |
| 2019 | 28.75 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 21.57 Million USD | -12.21% |
| 2024 Q1 | 24.57 Million USD | -12.02% |
| 2023 Q4 | 27.93 Million USD | -18.1% |
| 2023 FY | 27.93 Million USD | -45.11% |
| 2023 Q3 | 34.1 Million USD | -7.59% |
| 2023 Q2 | 36.9 Million USD | -12.06% |
| 2023 Q1 | 41.96 Million USD | -17.53% |
| 2022 Q2 | 53.62 Million USD | 8.99% |
| 2022 Q1 | 49.2 Million USD | -7.55% |
| 2022 FY | 50.88 Million USD | -4.39% |
| 2022 Q4 | 50.88 Million USD | -7.58% |
| 2022 Q3 | 55.05 Million USD | 2.67% |
| 2021 Q2 | 17.69 Million USD | -14.91% |
| 2021 Q4 | 53.21 Million USD | 246.61% |
| 2021 Q3 | 15.35 Million USD | -13.23% |
| 2021 FY | 53.21 Million USD | 120.48% |
| 2021 Q1 | 20.79 Million USD | -13.85% |
| 2020 FY | 24.13 Million USD | -16.05% |
| 2020 Q4 | 24.13 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 28.75 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 96.912% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 51.353% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 97.557% |
| Dynavax Technologies Corporation | 997.09 Million USD | 97.199% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 86.427% |
| Cosmos Health Inc. | 66.29 Million USD | 57.867% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 98.226% |
| Bright Green Corporation | 17.4 Million USD | -60.501% |
| PainReform Ltd. | 9.93 Million USD | -181.289% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2.139% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2.139% |
| SCYNEXIS, Inc. | 128.41 Million USD | 78.248% |
| Safety Shot Inc | 12.7 Million USD | -119.778% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -20.776% |
| Alpha Teknova, Inc. | 128.58 Million USD | 78.278% |
| Embecta Corp. | 1.21 Billion USD | 97.7% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 96.165% |
| Journey Medical Corporation | 76.84 Million USD | 63.653% |
| Procaps Group, S.A. | 460.18 Million USD | 93.93% |
| Theratechnologies Inc. | 77.76 Million USD | 64.083% |
| Harrow Health, Inc. | 311.75 Million USD | 91.04% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -87.551% |
| DURECT Corporation | 45.18 Million USD | 38.188% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.018% |
| Cronos Group Inc. | 1.13 Billion USD | 97.537% |
| OptiNose, Inc. | 107.72 Million USD | 74.072% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 94.071% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 50.076% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -21.195% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 93.928% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -134.365% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 65.843% |
| Radius Health, Inc. | 1.71 Billion USD | 98.372% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 47.582% |
| ProPhase Labs, Inc. | 91.92 Million USD | 69.615% |
| Phibro Animal Health Corporation | 982.18 Million USD | 97.156% |
| Procaps Group S.A. | 460.18 Million USD | 93.93% |
| Alvotech | 950.09 Million USD | 97.06% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 35.505% |
| Viatris Inc. | 47.68 Billion USD | 99.941% |
| Rockwell Medical, Inc. | 52.17 Million USD | 46.463% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 76.348% |
| SIGA Technologies, Inc. | 254.83 Million USD | 89.039% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.356% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 89.795% |
| Shineco, Inc. | 84.17 Million USD | 66.818% |
| PetIQ, Inc. | 868.22 Million USD | 96.783% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -231.018% |
| Incannex Healthcare Limited | 17.04 Million USD | -63.853% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.141% |
| Alimera Sciences, Inc. | 153.52 Million USD | 81.806% |
| Silver Spike Investment Corp. | 88.57 Million USD | 68.466% |
| Assertio Holdings, Inc. | 286.41 Million USD | 90.248% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -369.308% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 17.351% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 10.598% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -110.847% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 89.303% |
| Hempacco Co., Inc. | 18.04 Million USD | -54.807% |
| Talphera, Inc. | 20.39 Million USD | -36.955% |
| Alvotech | 950.09 Million USD | 97.06% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 93.123% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 98.308% |
| Currenc Group, Inc. | 141.49 Million USD | 80.259% |
| Kamada Ltd. | 351.96 Million USD | 92.064% |
| Indivior PLC | 1.95 Billion USD | 98.569% |
| Evoke Pharma, Inc. | 7.06 Million USD | -295.159% |
| Flora Growth Corp. | 23.62 Million USD | -18.226% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -110.847% |
| Evolus, Inc. | 188.99 Million USD | 85.221% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 97.817% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 98.154% |
| Akanda Corp. | 8.83 Million USD | -215.973% |